Furthermore, we found that elevated tumor B7-H3 expression was associated with a high risk of poor 5-year DFS in stage II-III patients who received postoperative adjuvant chemotherapy (HR=2.202, 95% CI=1.295-3.744, p=0.004, Table S3), suggesting that B7-H3 may limit the therapeutic efficacy of adjuvant chemotherapy. The gene discussed is CD276; the disease is neoplasm.